SCHEMBL5210213

SCHEMBL5210213

CCOC(=O)C(C)(Cc1ccc(OCc2ccccc2)cc1)Oc1cccc(F)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 3/20 0.49
▸ MAOB P27338 3/20 0.48
▸ PPARA Q07869 2/20 0.48
▸ GPR34 Q9UPC5 1/20 0.48
▸ PARP10 Q53GL7 1/20 0.46
▸ FFAR1 O14842 1/20 0.45
▸ GRM5 P41594 1/20 0.45
▸ PPARG P37231 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ MRGPRX4 Q96LA9 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ PKM P14618 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NR1H4 Q96RI1 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2807182 0.89 PPARG (0.55) NR4A2MAOBPPARAPARP10PPARG
SCHEMBL5209626 0.89 MAOB (0.47) NR4A2MAOBPPARAPPARGLMNA
SCHEMBL5112924 0.88 MAOB (0.50) MAOBPPARAPARP10FFAR1PPARG
SCHEMBL5112430 0.87 PPARA (0.43) NR4A2MAOBPPARAPPARGMRGPRX4
SCHEMBL14176244 0.87 LMNA (0.54) NR4A2MAOBPPARAPARP10PPARG
SCHEMBL5213397 0.86 PPARG (0.52) NR4A2MAOBPPARAPPARGLMNA
SCHEMBL5209756 0.85 MRGPRX4 (0.53) NR4A2MAOBPPARAPPARGLMNA
SCHEMBL5207761 0.85 PPARA (0.52) NR4A2MAOBPPARAPARP10FFAR1
SCHEMBL5113057 0.84 RAB9A (0.52) MAOBPPARAFFAR1PPARGLMNA
SCHEMBL5205181 0.83 MAOB (0.54) NR4A2MAOBPPARAFFAR1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313717-B1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS LILLY CO ELI (US) 2007-10-17 — — EP disclosed
US-7176224-B2 Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists ELI LILLY AND COMPANY (US) 2007-02-13 — — US disclosed
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists ELI LILLY AND COMPANY 2004-07-15 — — US disclosed
EP-1313717-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2003-05-28 — — EP disclosed
WO-2002016332-A1 OXAZOLYL-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS ELI LILLY AND COMPANY (US) 2002-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138277-A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists PPARA, PPARD, PPARG NR4A2 30/4885MAOB 3523/4885PPARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback